This site is intended for healthcare professionals only

Sponsored resources

Boehringer Ingelheim

For UK HCPs only

This virtual symposium is sponsored by Boehringer Ingelheim; product-related information will be discussed.

Click here for Pradaxa® (dabigatran etexilate) and Praxbind® (idarucizumab) prescribing information and adverse event reporting information
Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).


Choosing the right NOAC for the right patient for stroke prevention in NVAF

This promotional video presentation was originally broadcast on 5 May 2021.

Please note that the speaker(s) are not able to answer questions from attendees watching the video on-demand.

Company profile

Boehringer Ingelheim – a different kind of pharmaceutical company
Family-owned. Purpose-led. Innovation-driven: We serve mankind by improving health for people and animals.

Boehringer Ingelheim was first established in Germany in 1885 and is now one of the top 20 pharmaceutical companies in the world. To this day we remain family-owned, meaning we have the freedom to pursue our purpose – identifying health challenges of the future, and targeting areas of unmet need.

In human pharma, we do this through scientific innovation – taking on the biggest challenges in medicine. We invest in sustainable healthcare – planning for the long term alongside the NHS and our partners in the veterinary world. And we are driving digital transformation by investing in technology to accelerate healthcare improvements.

Pradaxa (150mg and 110mg hard capsules) is indicated for the prevention of stroke an systemic embolism in adult patients with non-valvular AF, with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age >75 years; heart failure (NYHA Class >II); diabetes mellitus; hypertension. 

Praxbind® (idarucizumab) is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa® (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required: for emergency surgery/urgent procedures; in life-threatening or uncontrolled bleeding.

For more information or to access the current prescriber guide or guide and Summary of Product Characteristics, please visit


  • AF; atrial fibrillation
  • NOAC; non-vitamin K antagonist oral anticoagulant
  • SPAF; stroke prevention in atrial fibrillation

Job code: PC-GB-104029 | Date of prep: May 2021

© Copyright Omniamed Communications. All Rights Reserved 108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom